Month: April 2022

Enlarge (credit: Getty Images | Aurich Lawson)

Earth Day is April 22, and its usual message—take care of our planet—has been given added urgency by the challenges highlighted in the latest IPCC report. This year, Ars is taking a look at the technologies we normally cover, from cars to chipmaking, and finding out how we can boost their sustainability and minimize their climate impact.

The term “restomod” first started gaining traction back in the 1990s. As muscle car enthusiasts searched for ways to improve the performance and reliability of their vintage machines, a cottage industry of folks adapting late-model powertrain and chassis components soon began to emerge. Today, you’d be hard-pressed to find a restored late-’60s Mustang or Camaro on the road that hasn’t been modified with some kind of modern tech—be it a computer-controlled fuel injection system, an updated brake and suspension system, or even a modern V8 engine.

To some, that might be sacrilege. To others, it’s simply about getting with the times.

Enlarge / A tray of prepared syringes for booster vaccinations with Moderna’s vaccine. (credit: Getty | Picture alliance)

A COVID-19 booster targeting two versions of the coronavirus in one shot offered stronger and broader protection than the current booster, which targets only one version, according to clinical trial results released this week by vaccine maker Moderna.

The results are preliminary and have not been peer reviewed or published in a scientific journal. But Moderna touted the findings as evidence that bivalent or multivalent vaccines—those that target two or more versions of the virus in a single shot—are the way forward for COVID-19 boosters.

Moderna and other vaccine makers are on a mission to develop boosters that could restore the once extraordinarily high levels of protection that mRNA-based COVID-19 vaccines initially provided, while also protecting against future variants. The first-generation mRNA vaccines were all designed to target the ancestral version of SARS-CoV-2 isolated in Wuhan, China—and they did so quite effectively, showing efficacy against symptomatic disease in the ballpark of 95 percent. But the virus has evolved into variants that can evade vaccine-derived protections. The latest variant, omicron, significantly reduced vaccine effectiveness against symptomatic disease, though protection against severe disease remains strong. Booster doses of the current vaccine design buoy protection but don’t restore the high levels seen previously. And the virus continues to evolve.